Peter Francis joined Janssen Oncology in October 2015 as a Medical Director focusing on prostate cancer, specifically abiraterone acetate, apalutamide and niraparib. He participates in multiple work streams in support of the prostate cancer franchise included key opinion leader engagement, advisory boards, promotional material review, business development, Real World evidence gathering as well as Sales Specialist and MSL training. He has also helped to develop several new clinical study concepts to fill in knowledge gaps in the management of prostate cancer. Peter draws on over 22 years of experience as a practicing hematologist-oncologist in Northern Virginia where he cared for patients with an extensive array of malignant and benign hematologic disorders and placed dozens of patients on clinical trials sponsored by the NCI as well as industry partners. He obtained his medical degree at the New York University School of Medicine in 1985 and finished a three-year internship and residency in Internal Medicine at the Boston Medical Center (combination of Boston University and Boston City Hospitals). He then spent 4 and ½ years at the National Cancer Institute, specializing in the preclinical development of antifungal drugs in a novel animal model system that is still generating data today. In 2007, Peter was in the graduating class of the George Washington University School of Business, completing a 2-year MBA program in Health Care with special interests in Health Policy and Pharmacoeconomics. He looks forward to daily challenges in advancing both of these pivotal therapies in the management of prostate cancer and introducing novel pipeline agents in solid tumors to internal and external stakeholders.
PHEN,Inc. © 2021 All rights reserved